Royce & Associates LP trimmed its position in shares of Bio-Techne Corp (NASDAQ:TECH - Free Report) by 65.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 272,065 shares of the biotechnology company's stock after selling 517,680 shares during the quarter. Royce & Associates LP owned 0.17% of Bio-Techne worth $19,717,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of TECH. Root Financial Partners LLC acquired a new stake in Bio-Techne in the 3rd quarter valued at $27,000. Financial Freedom LLC bought a new stake in Bio-Techne during the 3rd quarter valued at $30,000. Cassaday & Co Wealth Management LLC bought a new stake in Bio-Techne during the 1st quarter valued at $37,000. Avalon Trust Co bought a new stake in Bio-Techne during the 2nd quarter valued at $42,000. Finally, Allworth Financial LP acquired a new position in Bio-Techne during the second quarter worth $59,000. 98.95% of the stock is owned by institutional investors and hedge funds.
Bio-Techne Price Performance
Shares of NASDAQ:TECH opened at $72.80 on Monday. The stock has a market cap of $11.44 billion, a price-to-earnings ratio of 66.79, a PEG ratio of 5.28 and a beta of 1.29. Bio-Techne Corp has a 12-month low of $43.19 and a 12-month high of $72.88. The business's 50 day moving average is $72.53 and its 200 day moving average is $63.48.
Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.44. The business had revenue of $299.71 million during the quarter, compared to the consensus estimate of $292.60 million. Bio-Techne had a return on equity of 13.00% and a net margin of 13.95%. As a group, equities research analysts expect that Bio-Techne Corp will post 1.75 earnings per share for the current year.
Bio-Techne Cuts Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 23rd. Shareholders of record on Friday, November 13th will be issued a dividend of $0.08 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.32 dividend on an annualized basis and a yield of 0.4%. This is a negative change from Bio-Techne's previous quarterly dividend of $0.65. Bio-Techne's payout ratio is presently 29.36%.
Analyst Ratings Changes
A number of research analysts have weighed in on TECH shares. Weiss Ratings raised shares of Bio-Techne from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 25th. Argus cut shares of Bio-Techne from a "strong-buy" rating to a "strong sell" rating in a report on Monday, October 26th. Benchmark reissued a "hold" rating on shares of Bio-Techne in a research report on Wednesday, August 19th. Wells Fargo & Company lowered shares of Bio-Techne from an "overweight" rating to an "equal weight" rating and upped their target price for the stock from $62.00 to $73.00 in a report on Thursday, August 13th. Finally, Zacks Research upgraded shares of Bio-Techne from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $68.92.
Get Our Latest Stock Analysis on TECH
Bio-Techne Profile
(
Free Report)
Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.
Featured Articles
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bio-Techne, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.
While Bio-Techne currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.